Thomas Jonassen, MD

SynAct Pharma
Holte, Denmark

CSO, SynAct Pharma AB (publ)
Associate Professor
Faculty of Health Sciences
University of Copenhagen,
Denmark

Disclosure information not submitted.

Presentation(s):

• 1985: The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time